Manzanares J, Julian Md, Carrascosa A
Instituto de Neurociencias de Alicante, Universidad Miguel Hernandez-Consejo Superior de Investigaciones Cientificas, Apartado de correos 18, 03550 Sant Joan d'Alacant, Spain.
Curr Neuropharmacol. 2006 Jul;4(3):239-57. doi: 10.2174/157015906778019527.
Cannabis extracts and synthetic cannabinoids are still widely considered illegal substances. Preclinical and clinical studies have suggested that they may result useful to treat diverse diseases, including those related with acute or chronic pain. The discovery of cannabinoid receptors, their endogenous ligands, and the machinery for the synthesis, transport, and degradation of these retrograde messengers, has equipped us with neurochemical tools for novel drug design. Agonist-activated cannabinoid receptors, modulate nociceptive thresholds, inhibit release of pro-inflammatory molecules, and display synergistic effects with other systems that influence analgesia, especially the endogenous opioid system. Cannabinoid receptor agonists have shown therapeutic value against inflammatory and neuropathic pains, conditions that are often refractory to therapy. Although the psychoactive effects of these substances have limited clinical progress to study cannabinoid actions in pain mechanisms, preclinical research is progressing rapidly. For example, CB(1)mediated suppression of mast cell activation responses, CB(2)-mediated indirect stimulation of opioid receptors located in primary afferent pathways, and the discovery of inhibitors for either the transporters or the enzymes degrading endocannabinoids, are recent findings that suggest new therapeutic approaches to avoid central nervous system side effects. In this review, we will examine promising indications of cannabinoid receptor agonists to alleviate acute and chronic pain episodes. Recently, Cannabis sativa extracts, containing known doses of tetrahydrocannabinol and cannabidiol, have granted approval in Canada for the relief of neuropathic pain in multiple sclerosis. Further double-blind placebo-controlled clinical trials are needed to evaluate the potential therapeutic effectiveness of various cannabinoid agonists-based medications for controlling different types of pain.
大麻提取物和合成大麻素仍被广泛视为非法物质。临床前和临床研究表明,它们可能有助于治疗多种疾病,包括与急慢性疼痛相关的疾病。大麻素受体、其内源性配体以及这些逆行信使的合成、运输和降解机制的发现,为我们提供了用于新型药物设计的神经化学工具。激动剂激活的大麻素受体可调节痛觉阈值、抑制促炎分子的释放,并与其他影响镇痛的系统(尤其是内源性阿片系统)产生协同作用。大麻素受体激动剂已显示出对炎症性疼痛和神经性疼痛的治疗价值,而这些病症通常对治疗具有抗性。尽管这些物质的精神活性作用限制了在疼痛机制中研究大麻素作用的临床进展,但临床前研究正在迅速推进。例如,CB(1)介导的肥大细胞激活反应抑制、CB(2)介导的对位于初级传入通路中的阿片受体的间接刺激,以及内源性大麻素转运体或降解酶抑制剂的发现,都是表明可避免中枢神经系统副作用的新治疗方法的近期研究结果。在本综述中,我们将研究大麻素受体激动剂缓解急慢性疼痛发作的有前景的适应症。最近,含有已知剂量四氢大麻酚和大麻二酚的大麻提取物已在加拿大获批用于缓解多发性硬化症中的神经性疼痛。需要进一步的双盲安慰剂对照临床试验来评估各种基于大麻素激动剂的药物控制不同类型疼痛的潜在治疗效果。